Jeffrey Eisele
Chief Development Officer · Apellis Pharmaceuticals, Inc.
- 2024
- Dec 27, 2024
- 1
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Jeffrey Eisele files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Cedric Francois - $980K in APLS purchases and sales in the last 12 months
- David O. Watson - $697K in APLS purchases and sales in the last 12 months
- Timothy Eugene Sullivan - $647K in APLS purchases and sales in the last 12 months
- Nur Nicholson - $270K in APLS purchases and sales in the last 12 months
- Pascal Deschatelets - $198K in APLS purchases and sales in the last 12 months
- Caroline Baumal - $175K in APLS purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Jeffrey Eisele?
Jeffrey Eisele is a corporate insider, tracked as Chief Development Officer of Apellis Pharmaceuticals, Inc. (APLS). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Jeffrey Eisele last file a Form 4?
The only primary Form 4 on record is dated 27 December 2024.
Has Jeffrey Eisele been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($2K) across all tracked filings.
